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ABSTRACT
Chronic necrotizing pulmonary aspergillosis (CNPA), a form of chronic pulmonary 
aspergillosis (CPA), affects immunocompetent or mildly immunocompromised persons 
with underlying pulmonary disease. These conditions are associated with high morbidity 
and mortality and often require long-term antifungal treatment. The long-term prognosis 
for patients with CNPA and the potential complications of CNPA have not been well 
documented. The aim of this study was to review published papers that report cases of CNPA 
complications and to highlight risk factors for development of CNPA. The complications 
in conjunction associated with CNPA are as follows: pseudomembranous necrotizing 
tracheobronchial aspergillosis, ankylosing spondylarthritis, pulmonary silicosis, acute 
respiratory distress syndrome, pulmonary Mycobacterium avium complex (MAC) disease, 
superinfection with Mycobacterium tuberculosis, and and pneumothorax. The diagnosis 
of CNPA is still a challenge. Culture and histologic examinations of bronchoscopically 
identified tracheobronchial mucus plugs and necrotic material should be performed in all 
immunocompromised individuals, even when the radiographic findings are unchanged. Early 
detection of intraluminal growth of Aspergillus and prompt antifungal therapy may facilitate 
the management of these patients and prevent development of complications.
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INTRODUCTION
Aspergillus infection of the lung manifests in a wide spectrum of conditions 
ranging from saprophytic colonization to hypersensitivity reactions to necrotizing 
pneumonia with angioinvasion1. In the saprophytic form of the disease, 
aspergillomas establish themselves in pre-existing cavities. The chronic cavitary 
form of aspergillosis, which produces a slowly progressive infiltrate that may include 
mycetoma, was proposed in 1981 as a new category of semi-invasive pulmonary2 or 
chronic necrotizing pulmonary aspergillosis (CNPA)3. CNPA is a form of chronic 
pulmonary aspergillosis (CPA), often presenting with rapid progressive infection 
(< 3 months) in moderately immunocompromised patients, which should be 
managed as invasive aspergillosis1. Aspergillus has a propensity to invade pulmonary 
blood vessels, resulting in pulmonary infarction and subsequent development of 
necrotic cavities and bronchus dilatation4. Lung conditions affecting the pulmonary 
defense system, such as previous surgical resection, ionizing radiation therapy, or 
chronic obstructive pulmonary disease (COPD), allow Aspergillus to penetrate the 
lung through enzyme secretion despite the absence of cavities5. In addition to COPD, 
other conditions commonly associated with CNPA include previous pulmonary 
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tuberculosis (TB), atypical Mycobacterium tuberculosis 
infection, cystic fibrosis, pulmonary infarction, pulmonary 
fibrosis, previous surgery, and pneumoconiosis6-8. 
Other conditions that may be associated with the 
development of CNPA include lung cancer, stage III or IV 
fibrocystic pulmonary sarcoidosis, and silicosis6-8. Other 
immunosuppression conditions such as diabetes mellitus, 
malnutrition, alcoholism, connective tissue diseases, and 
prolonged corticosteroid therapy also increase the risk for 
development of CNPA1,2. Complications of CNPA usually 
occur because of leakage of air from an air-filled lung cavity 
into the pleural space. These conditions are associated with 
high morbidity and mortality and often require long-term 
antifungal treatment9. The long-term prognosis for patients 
with CNPA and potential complications of CNPA have not 
been well documented. The aim of this study was to review 
published papers reporting cases of CNPA complications 
and to highlight risk factors for development of CNPA.
Pseudomembranous necrotizing tracheobronchial 
aspergillosis and CNPA
The Oh et al.10 reported a case of pseudomembranous 
necrotizing tracheobronchial aspergillosis in an 
immunocompetent host. They reported a rare case 
of Aspergillus pseudomembranous tracheobronchitis 
without an invasion of the pulmonary parenchyma 
that developed in an immunocompetent patient10. 
Aspergillus tracheobronchitis was confined, at least 
initially, to the airways with only a superficial mucosal 
invasion, and the diagnosis was delayed because of 
non-specific signs, symptoms, and lack of radiographic 
abnormalities11.  Pseudomembranous necrotizing 
tracheobronchial aspergillosis has been reported recently 
as an uncommon form of airway invasive aspergillosis 
in immunocompromised patients10,12-15. In a review of 
the literature on Aspergillus tracheobronchitis, including 
all forms of tracheobronchial involvement, reports 
indicated that the disease was progressive and fatal in 
about 40% of cases10,13-15. This was apparently a lethal 
variant of tracheobronchial aspergillosis with a markedly 
higher mortality rate and more parenchymal lung 
involvement (65%) compared with all cases of Aspergillus 
tracheobronchitis (45%)10,15. It presents an extensive 
transmural necrotizing bronchitis with pseudomembrane 
formation that develops in immunocompromised patients, 
and it is usually characterized by a limited extension of 
inflammation and hyphae into the peribronchial tissue, 
without an invasion of the pulmonary parenchyma10,12. 
Involvement of the bronchial tree can be invasive, leading 
to a pseudomembranous tracheobronchitis with extensive 
bronchial hemorrhage and invasion of the bronchial walls 
and vessels. In the literature review, we found reports of 
22 cases with this variant of tracheobronchial involvement 
by Aspergillus12-15. There are published only five reports 
of this disease developing in an immunocompetent or 
mildly immunocompromised patient. The first case 
revealed cutaneous anergy and lymphopenia involving 
T cells and NK cells, related to a recent influenza A 
infection16. In the second case, there were “grayish” 
mucus plugs in several segmental bronchi on autopsy 
and focally limited extension into the adjacent lung 
parenchyma17. The third case revealed the presence 
of fungal invasion through the bronchial wall into the 
adjacent lung parenchyma and pulmonary arteries17. 
The fourth case was a 70-year-old man with many risk 
factors, including corticosteroid use. The fifth case was a 
66-year-old with underlying COPD17. This patient had no 
risk factors associated with an immunocompromised state, 
and had no invasion of the parenchyma, or atelectasis, 
but his condition rapidly progressed to severe CO2 
retention and respiratory failure. Pseudomembranous 
necrotizing tracheobronchial aspergillosis should be 
considered as potential complication of CNPA even in an 
immunocompetent host10,15,16.
Ankylosing spondylarthritis and CNPA
Fibro-bullous disease is a late complication of 
ankylosing spondylarthritis17,18. Its radiologic features 
frequently mimics tuberculosis or excavated neoplasm. 
About 50 to 65% of patients with ankylosing spondylarthritis 
have chronic Aspergillus colonization of their airways17. 
Pulmonary aspergillosis infection occurs in 10 to 30% 
during evolution. Pontier et al. reported two cases of patients 
with spondylarthritis who developed chronic necrotizing 
pulmonary aspergillosis17. Diagnosis was based on serology, 
mycologic examination of expectoration and in one case, 
on histology obtain by transbronchial biopsies. Pulmonary 
complications due to Aspergillus species frequently 
reveal associated fibro-bullous disease in patients with 
ankylosing spondylarthritis. The fibroblastic disease is 
often asymptomatic and, as in the reported cases, its clinical 
revelation is often linked to a complication (bacterial or 
fungal infections, tuberculosis, pneumothorax, etc.). In one 
case, it was associated with unilateral, pseudo-tuberculosis, 
with a preferential apical location and pleural involvement. 
In cases with ankylosing spondylarthritis and CNPA, there 
is usually bilateral and asymmetric pachypleuritis17-19. 
This is a rare complication of spondylitis in about 1.3% of 
patients18, with male predominance and it is estimated that it 
is revealed on average 17 years after the spinal signs. There 
Rev Inst Med Trop São Paulo. 2017;59:e19
Complications of chronic necrotizing pulmonary aspergillosis
Page 3 of 7
is no specific predictive factor (HLA B27 antigen positive 
in 50% of cases)18. The two patients reported by Pontier 
et al.17, had no previously known pulmonary pathology17. 
At the anatomo-pathologic level, lesions of inter-alveolar 
fibrosis with hyaline fibrosis and non-specific lymphocytic 
and macrophage infiltrates were found17. The origin of this 
fibrosis is currently unknown but several hypotheses have 
been suggested: an inflammatory fibrosis aggravated or 
caused by repeated infectious episodes, a hypoventilation of 
the apexes favored by the restrictive syndrome and systemic 
inflammatory attack comparable with the involvement of 
other organs17-19. The evolution can be towards chronic 
respiratory insufficiency.
Semi-invasive pulmonary aspergillosis or CNPA occurs 
in 10-30% of cases of fibroblastic disease. It is a frequent 
mode of revelation17-19. Unlike aspergilloma, there is no pre-
existing cavity, and no walls are built. It is probably favored 
by hypoventilation of the vertices during spondylitis. It may 
develop into fibroblastic sequelae. The question arises as to 
whether fibroblastic disease is a sequela of semi-invasive 
pulmonary aspergillosis or pre-existing in asymptomatic 
form. In both cases, semi-invasive aspergillosis is 
manifested as severe broncho-pneumonia, resistant to 
antibiotics, and potentially fatal17. The general clinical 
sign predominates and distinguishes it from aspergilloma. 
Pontier et al.17 describe the acute form, evolving in a few 
weeks towards pneumonic block and signs of suppuration, 
and sub-acute form, with a pseudo-tuberculous picture 
evolving towards necrosis. In the cases presented by Pontier 
et al.17, a radio-clinical picture of intra-cavitary aspergillosis 
was demonstrated after favorable response to antifungal 
treatment. Although cases of isolated aspergilloma have 
been described in patients with ankylosing spondylitis 
with fibroblastic lesions17-19, in the two cases published 
by Pontier et al.17, were probably a result of low-lying 
progression of semi-invasive aspergillosis previously 
incompletely controlled by medical treatment.
Pulmonary silicosis and CNPA
Blanco et al.20 reported three cases with a long history 
of exposure to silica dust with pulmonary aspergillosis 
complicated bu progressive massive fibrosis (PMF)20. 
Pneumoconiosis, which causes deterioration of local 
immunity, is less frequent, limited to 2% and 3% of 
cases21,22. The three cases presented by Blanco et al.20 
presented had a history of tuberculosis, which was variably 
described in the literature (between 11% and 93%)21,22. 
Frequent treatment with steroids in the first patient and 
a history of alcoholism in the second patient probably 
contributed to the predisposition for CNPA20. On the other 
hand, all three had been active smokers20, a history referred 
to in 53% of the patients reported by Nam et al.23 but not 
mentioned in the other series. Compared with Nam et al.23 
reports, in which the youngest patient was 48 years old and 
only 20% had large opacities, patients reported by Blanco 
et al.20 were younger and PMF was observed in all three 
cases. These patients usually present with fever, cough and 
weight loss, and less frequently dyspnea or chest pain. The 
three patients reported by Blanco et al.20 had hemoptysis 
and mycetoma20, which is reported in 49% and 90% of 
cases in the literature21-23. Radiologically, the presence of 
infiltrates in the upper lobes, cavitation, nodular opacities, 
and pleural thickening are the most common findings that 
coincide with silicosis in patients with CNPA20-23.
CNPA can be serious, fatal if untreated, and may be 
accompanied by acute respiratory distress syndrome23-24. 
CNPA can also play a relevant role in the mortality of 
patients with silicosis. The study by Iossifova et al.25 
showed that people with CNPA and silicosis are almost 
10 times more likely to die than people without silicosis. 
In addition, in young patients, lung transplantation could 
be contraindicated, as shown in the first case reported by 
Blanco et al.20.
Given the high mortality, the diagnosis of CNPA in 
patients with silicosis should be considered as soon as 
possible, especially if there are any signs of new infiltrates, 
mycetomas, and anamnestic data of active smoking or a 
history of TB20-24.
Acute respiratory distress syndrome and CNPA
Yano24 published a report of a patient with acute 
respiratory distress syndrome (ARDS) who died because 
of CNPA. This patient had pulmonary fibrosis of unknown 
cause with a right upper bulla. Mycetoma in the bulla, 
invaded the tissue adjacent to the bulla, as the wall of the 
right upper bulla became thicker with surrounding lung 
infiltration24. This patient developed ARDS because of 
CNPA after Aspergillus invaded these tissues leading to 
fatal respiratory failure. The patient had a cerebral accident 
6 days after respiratory failure, probably as a result of septic 
emboli accompanied with CNPA. Depending on the size 
of the emboli, nuclear magnet resonance (NMR) findings 
may vary from major arterial branch infarction to multiple 
small abscesses located at the gray-white matter junction, 
secondary to occlusion of small arteries and arterioles25,26. 
Small abscesses are accompanied by surrounding oedema 
and mass effect, which is well demonstrated on NMR1. One 
day before the first cerebral accident in case reported by 
Yano24, the percentage of serum eosinophils increased to 
13%; after the first cerebral attack, the increased percentage 
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of eosinophils persisted at around 13-22%. This peripheral 
eosinophilia may reflect activation of the lung aspergillus 
lesion. It is important to consider that ARDS may occur 
in cases of CNPA and that peripheral eosinophilia might 
forebode worsening of CNPA24-28.
Pulmonary Mycobacterium avium complex disease 
and CNPA
Pulmonary aspergilloma is an important complication 
occurring in cavities remaining after pulmonary TB, 
and it has been reported as a complication in 15% of 
patients with sequelae of pulmonary TB28-30. Although 
the most frequent underlying disease with pulmonary 
aspergillosis was pulmonary TB29, there are no detailed 
reports regarding the formation of pulmonary aspergilloma 
including CNPA with a fungus ball in a cavity formed by 
pulmonary Mycobacterium avium intracellular complex 
(MAC). Kobashi et al.30 reported a case of CNPA in which 
a fungus ball appeared in a growing cavity transitionally 
formed by pulmonary MAC, during a follow-up period 
after treatment30. The most frequently reported underlying 
disease in cases of pulmonary aspergilloma including 
CNPA is sequela of pulmonary TB (25-72%), secondary to 
a pre-existing intrapulmonary cavity such as a pulmonary 
cyst29,31,32. There have been a few reports of superinfection 
by Aspergillus spp. of pulmonary lesions caused by 
Mycobacterium xenopi33,34. However, the frequency of 
nontuberculous mycobacteria (MAC, etc.) has recently 
increased among patients with pulmonary mycobacterial 
diseases, especially in industrialized nations29. In addition, 
there are many cases in previous reports in which the 
underlying disease of pulmonary aspergilloma including 
CNPA was a cavity formed by a pulmonary nontuberculous 
mycobacterial, rather than a cavity formed by pulmonary 
TB29-34. The clinical symptoms caused by pulmonary 
aspergilloma vary in accordance with the severity of the 
underlying pre-existing pulmonary disease, but a common 
characteristic has been hemosputum or haemoptysis29-34. 
The chief complaint in the case presented by Kobashi et 
al.30 was continuous fever, which suggests that the patient 
probably developed the condition, which suddenly destroyed 
the lung, as semi-invasive pulmonary aspergillosis or 
CNPA, rather than pulmonary aspergilloma. Denning31 also 
reported that patients with pulmonary aspergilloma with 
clinical symptoms such as fever and cachexia usually have 
undiscovered CNPA, rather than pulmonary aspergilloma. 
The patient presented by Denning31 had a mixed infection 
caused by A. niger and M. avium, although it has been 
commonly mentioned that A. fumigatus is the most frequent 
isolate from patients with CNPA. Kawamura et al.30 and 
Perfect et al.32 reported isolation rates of A. fumigatus of 
75% and 80%, respectively; the rates for A. niger were 9% 
and 10%, respectively.
With regard to the laboratory findings, it has been 
reported32-35 that tumor markers (carcinoembryonic antigen, 
squamous cell carcinoma antigen, carbohydrate antigens 
sialyl Lewis, and sialyl SSEA-1) are often increased in 
several benign diseases such as pulmonary mycobacterial 
diseases, and the percentage increase of these tumor 
marker is 15-62%. Histologically, these tumor markers 
were expressed in mucous cells of the bronchial gland and 
the surface of bronchiolar surface epithelium cells29,31-33. 
Consequently, it is suspected that serum tumor markers are 
increased in cases of hyperplasia of bronchiolar epithelium 
cells or mucous cells of bronchial gland, because of the 
existing chronic respiratory infection with bronchiectasis 
caused by pulmonary MAC29,31-33. The case presented 
by Kobashi et al.30 serves as a reminder that pulmonary 
nontuberculous mycobacterial disease has become one 
of the underlying pulmonary diseases complicated by 
CNPA. In order to detect fast CNPA with a fungus ball 
as a complication, it is important to perform periodic 
radiological examinations (chest computed tomography 
[CT]), serological examinations (anti-Aspergillus antibody) 
and sputum culture examinations during the follow-up 
period of an underlying respiratory disease29-34.
Superinfection by Mycobacterium tuberculosis and 
CNPA
Although aspergillosis is commonly found in old 
tuberculous cavities, pulmonary aspergillosis is rarely 
complicated by active pulmonary TB34,35. Kohno et al.36 
presented a rare case of CNPA complicated by active 
pulmonary TB. The case is unusual because the necrotic 
granuloma of aspergillosis contained a few acid-fast 
bacilli in the necrotic foci. Colonization of pre-existing 
TB pulmonary lesions by Aspergillus species is well 
known; however, superinfection by Aspergillus of a cavity 
already infected by Mycobacterium is rare34. Binder et 
al.3 reported a case of CNPA with a moderate number of 
acid-fast bacilli, but commented that this might have been 
colonization by non-tuberculosis mycobacteria. Because 
the necrotic granuloma consisted mainly of Aspergillus 
hyphae, it is more likely that aspergillosis was the main 
lesion with M. tuberculosis superinfection. It is impossible 
to completely rule out the possibility that this case was an 
instance of aspergillosis invading a healed tuberculous 
lesion, but the pathologic features of CNPA are unique and 
characteristic34. Superinfection of CNPA with Xanthomonas 
maltophilia has also been reported, but it is rare3.
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Pneumothorax and CNPA
Adzic-Vukovic et al. reported a rare and unusual case 
of pneumothorax in an immunocompetent patient with 
CNPA35. To our knowledge, this is the first reported case in 
Europe. A 40-year old woman, with body mass index less 
than 15 kg/m2 and high-grade fever developed symptoms of 
acute onset of breathlessness, dry cough, and chest pain on 
the left side. The left side of the chest was hyper-resonant 
and breath sounds were weak. Laboratory results excluded 
common variable immune deficiencies, but on the other 
hand, the patient could not be considered as clinically 
immunocompetent because she had end-stage COPD and 
cachexia. Radiography showed a left-sided pneumothorax 
with contralateral cavitation and an intercostal drainage 
underwater seal was applied (Figure 1). Four days later, 
CT scan of the thorax indicated the presence of possible 
necrotizing lesions bilaterally (Figure 1). Fiber-optic 
bronchoscopy was done and a tissue sample was taken. 
Serological analyses revealed a positive galactomannan index 
(2.19) in bronchoalveolar lavage (BAL), as well as a positive 
value for anti-Aspergillus IgG Ab in serum (280 UI/mL). 
Patho-histologic analyses of the tissue sample confirmed 
the presence of fungal hyphae, and culture was positive for 
A. fumigatus (Figure 1). The patient responded positively to 
antifungal therapy; her general condition improved with rapid 
radiographic improvement in 2 weeks. During a follow-up 
period of 1 year, there was no disease regression35.
Pneumothorax as a result of rupture of aspergilloma 
into the pleural space in non-immunocompromised patients 
is extremely rare8. Pneumothorax has been reported in 
granulocytopenic patients undergoing intensive cytotoxic 
therapy for hematologic malignancies8. In this case, the 
patient was immunocompetent according to the laboratory 
parameters, but clinically she was immunocompromised 
with end-stage COPD and cachexia35. Surprisingly, the 
patient developed pneumothorax as a complication of the 
rupture of aspergilloma into the pleural space. Long-term 
weight loss, low body mass index and untreatable end-stage 
COPD should be considered as possible cause of spontaneous 
pneumothorax in this patient. Pneumothorax increases both 
short-and long-term morbidity and mortality in patients with 
CNPA and causes significant deterioration of their quality of 
life. This case highlights that a diagnosis of CNPA should 
be considered in patients with end-stage COPD, a low body 
mass index, or patients who develop pneumothorax. 
CONCLUSION
Diagnosis of CNPA is still a challenge. A chest 
radiograph is not helpful to the diagnosis for several 
reasons: (1) usually because of normal radiologic 
findings, intraluminal mycetomas may not be readily 
detectable, (2) Aspergillus may enlarge so rapidly that 
recent chest radiographs may not reveal atelectasis, and 
(3) the lung parenchyma is usually unaffected37. A chest 
CT scan is much more helpful in the early diagnosis and 
aids further diagnostic studies, such as bronchoscopies 
and open-lung biopsies. Although a CT scan is helpful 
in the diagnosis of airway aspergillosis, diagnosis of 
this specific disease cannot be made based on imaging 
features alone. Bronchoscopy, apart from providing 
specimens for microbiological examination, is a useful 
method for detecting infections with endobronchial 
manifestations37. It should be recommended as early as 
possible for diagnosis and to maintain airway patency, at a 
time when it is most feasible37-39. A presumptive diagnosis 
is made when the fungus is isolated from bronchial 
aspirates or BAL cultures, and a definitive diagnosis is 
made when there is histologic demonstration of invasion 
of the mucosa by hyphae37-39. Therefore, culture and 
histologic examinations of bronchoscopically identified 
tracheobronchial mucus plugs and necrotic material should 
be performed in all immunocompromised individuals, 
even when the radiographic finding are unchanged. Early 
detection of intraluminal growth of Aspergillus and prompt 
antifungal therapy may facilitate the management of these 
patients and prevent development of complications.
ACKNOWLEDGEMENT
The paper has been published with the support of the 
Ministry of Education, Science and Technology of the 
Republic of Serbia (Project No. III45005).
Figure 1 - 1A) Left sided pneumothorax with a contralateral 
cavitation; 1B) Bilateral cavity lesions; 1C) Computed 
tomography scan showed bilateral necrotising pulmonary 
lesions; 1D) Radiographic regression after two weeks of 
voriconazole treatment.
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